Lauren Merendino
CIK 1855298 · Chief Commercial Officer · last filed 2026-04-23
Lauren Merendino is a Chief Commercial Officer who has filed 18 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for DAWN, was dated Apr 23, 2026. Across all open-market trades the lifetime net is −$343.2K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
18
-$343.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Chief Commercial Officer | 0 | $21.53 | $0 | -$150.7K | 7 | 2026-04-23 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | — | $0.20 | — | $0 | 1 | 2024-03-28 |
| Myovant Sciences Ltd. (MYOV) Delisted | Chief Commercial Officer | 147,747 | $26.98 | $3.99M | -$192.5K | 7 | 2023-03-10 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-23 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Disp (D) | −60,157 | $0 | EDGAR |
| 2026-02-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +9,348 | -$67.4K | EDGAR |
| 2026-02-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −5,814 | -$67.4K | EDGAR |
| 2026-01-30 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-11-18 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,810 | -$33.2K | EDGAR |
| 2025-11-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −3,726 | -$33.2K | EDGAR |
| 2025-11-07 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | — | $0 | EDGAR |
| 2025-08-19 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,770 | -$25.5K | EDGAR |
| 2025-05-19 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,609 | -$24.6K | EDGAR |
| 2025-05-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −3,927 | -$24.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.